This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study on Thrombosis Therapy in German Cancer Patients

This study has been completed.
Information provided by (Responsible Party):
LEO Pharma Identifier:
First received: March 1, 2012
Last updated: August 14, 2014
Last verified: November 2013
The study aims to document the flow of German patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.

Condition Intervention
Cancer Deep Vein Thrombosis Pulmonary Embolism Other: no intervention is being made

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study on Thrombosis Therapy in German Cancer Patients

Resource links provided by NLM:

Further study details as provided by LEO Pharma:

Primary Outcome Measures:
  • treatment time on low molecular weight heparin [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • patient pathways [ Time Frame: 1 year ]
    data collection on patient pathway: who is the referring physician, physician who diagnoses deep vein thrombosis (DVT)

  • risk factors for DVT [ Time Frame: 1 year ]

Enrollment: 76
Study Start Date: February 2012
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
all eligible patients
there is only 1 Cohort in which all patients participating in this NIS are included
Other: no intervention is being made
This is a Non-Interventional Study (NIS)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Cancer patient with acute deep vein throbosis/ pulmonary embolism in ambulatory oncology care/practice

Inclusion Criteria:

  • patient with cancer and acute deep vein thrombosis and/or pulmonary embolism

Exclusion Criteria:

  • life expectancy less that 6 months
  • age less that 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01559883

Prof. Dr. Axel Matzdorff
Saarbrücken, Saarland, Germany, 66111
Sponsors and Collaborators
LEO Pharma
Principal Investigator: Axel Matzdorff, Prof.Dr. Caritasklinikum Saarbrücken, St. Theresia
  More Information

Responsible Party: LEO Pharma Identifier: NCT01559883     History of Changes
Other Study ID Numbers: DE-Thrombose-NIS-2012
Study First Received: March 1, 2012
Last Updated: August 14, 2014

Keywords provided by LEO Pharma:
pulmonary embolism
low molecular weight heparin

Additional relevant MeSH terms:
Pulmonary Embolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases processed this record on September 21, 2017